脓毒症中延长输注与间歇输注β-内酰胺类抗生素的比较:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析纳入15项随机对照试验、共2130例脓毒症成人患者,比较延长输注与间歇输注β-内酰胺类抗生素的效果。延长输注组全因死亡率显著降低(RR 0.83,95%CI 0.72-0.97,P=0.02),临床成功率显著提高(RR 1.16,95%CI 1.03-1.31,P=0.02),微生物学成功率和不良事件无显著差异。亚组分析显示,在每组样本量超过20例、2010年后开展的研究、以革兰阴性菌感染为主、给予负荷剂量及使用青霉素的亚组中,延长输注均与死亡率降低相关。
要点
- 在2130例脓毒症成人患者中,延长输注β-内酰胺类抗生素较间歇输注显著降低全因死亡率(RR 0.83,95%CI 0.72-0.97,P=0.02)。
- 延长输注组临床成功率显著高于间歇输注组(RR 1.16,95%CI 1.03-1.31,P=0.02)。
- 两组不良事件无显著差异(RR 0.91,95%CI 0.64-1.29,P=0.60),微生物学成功率无统计学显著差异(RR 1.10,95%CI 0.98-1.23,P=0.11)。
- 亚组分析中,以革兰阴性菌感染为主(RR 0.81,95%CI 0.68-0.96,P=0.02)及使用青霉素(RR 0.61,95%CI 0.38-0.98,P=0.04)的亚组,延长输注降低死亡率的关联更明显。
适用人群与场景
- 成人脓毒症患者(15项随机对照试验,共2130例)。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入15项随机对照试验,共2130例脓毒症成人患者;检索PubMed、EMBASE和Cochrane Library数据库;采用随机效应模型;PROSPERO注册号CRD42023463905。
- 主要终点:延长输注组较间歇输注组全因死亡率显著降低(RR 0.83,95%CI 0.72-0.97,P=0.02);临床成功率显著提高(RR 1.16,95%CI 1.03-1.31,P=0.02)。
- 次要终点:微生物学成功率无统计学显著差异(RR 1.10,95%CI 0.98-1.23,P=0.11);不良事件无显著差异(RR 0.91,95%CI 0.64-1.29,P=0.60)。
- 亚组分析:每组样本量超过20例的研究中,延长输注组死亡率降低(RR 0.84,95%CI 0.72-0.98,P=0.03);2010年后开展的研究中,延长输注组死亡率降低(RR 0.84,95%CI 0.72-0.98,P=0.03);以革兰阴性菌感染为主的病例中,延长输注组死亡率降低(RR 0.81,95%CI 0.68-0.96,P=0.02);给予负荷剂量的研究中,延长输注组死亡率降低(RR 0.84,95%CI 0.72-0.97,P=0.02);使用青霉素的研究中,延长输注组死亡率降低(RR 0.61,95%CI 0.38-0.98,P=0.04)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入15项随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于成人脓毒症患者,延长输注β-内酰胺类抗生素较间歇输注可能降低全因死亡率并提高临床成功率,且不增加不良事件;该结论基于15项随机对照试验的Meta分析。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The two latest studies on prolonged versus intermittent use of β-lactam antibiotics in patients with sepsis did not reach consistent conclusions, further contributing to the controversy surrounding the effectiveness of the prolonged β-lactam antibiotics infusion strategy. We conducted a systemic review and meta-analysis to evaluate the efficacy and safety of prolonged and intermittent β-lactam infusion in adult patients with sepsis.
METHODS: We systematically searched PubMed, EMBASE, and Cochrane Library databases for original randomized controlled trials comparing prolonged and intermittent β-lactam infusion in sepsis patients. A random-effects model was used to evaluate mortality, clinical success, microbiological success, and adverse events. We also conducted subgroup analyses to explore the impact of various factors on the mortality rates. Relative risk (RR) and corresponding 95% confidence intervals (CIs) were used to calculate the overall effect sizes for dichotomous outcomes. This meta-analysis was registered in PROSPERO (CRD42023463905).
RESULTS: We assessed 15 studies involving 2130 patients. In our comprehensive assessment, we found a significant reduction in all-cause mortality (RR, 0.83; 95% CI 0.72-0.97; P = 0.02) and a notable improvement in clinical success (RR, 1.16; 95% CI 1.03-1.31; P = 0.02) in the prolonged infusion group compared to the intermittent infusion group, whereas microbiological success did not yield statistically significant results (RR, 1.10; 95% CI 0.98-1.23; P = 0.11). No significant differences in adverse events were observed between the two groups (RR, 0.91; 95% CI 0.64-1.29; P = 0.60). Additionally, remarkable conclusions were drawn from subgroup analyses including studies with sample sizes exceeding 20 individuals per group (RR, 0.84; 95%CI 0.72-0.98; P = 0.03), research conducted post-2010 (RR, 0.84; 95%CI 0.72-0.98; P = 0.03), cases involving infections predominantly caused by Gram-negative bacteria (RR, 0.81; 95%CI 0.68-0.96; P = 0.02), as well as the administration of a loading dose (RR, 0.84; 95% CI 0.72-0.97; P = 0.02) and the use of penicillin (RR, 0.61; 95% CI 0.38-0.98; P = 0.04).
CONCLUSIONS: Compared to intermittent infusion, prolonged infusion of β-lactam antibiotics significantly decreases all-cause mortality among patients with sepsis and enhances clinical success without increasing adverse events.
参考来源
- Zhao Y, Zang B, Wang Q, et al. Prolonged versus intermittent β-lactam infusion in sepsis: a systematic review and meta-analysis of randomized controlled trials. Ann Intensive Care. 2024. PMID: 38368588. doi:10.1186/s13613-024-01263-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。